S10 phosphorylation of p27 mediates atRA induced growth arrest in ovarian carcinoma cell lines

Maria Radu1, Dianne R Soprano, Kenneth J Soprano

  • 1Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, Pennsylvania, USA.

Insights

All trans retinoic acid (atRA) inhibits ovarian cancer cell growth by increasing p27 protein phosphorylation. This specific modification is crucial for atRA

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • All trans retinoic acid (atRA) is known to inhibit ovarian carcinoma cell growth.
  • p27 is a cyclin-dependent kinase inhibitor whose levels are elevated by atRA.

Purpose of the Study:

  • To investigate the role of p27 phosphorylation at the S10 residue in mediating atRA-induced growth arrest in ovarian cancer cells.
  • To compare the effects of atRA on sensitive (CAOV3) versus resistant (SKOV3) cell lines.

Main Methods:

  • Treatment of CAOV3 and SKOV3 cells with atRA.
  • Analysis of p27, phospho-p27 (S10), and skp2 protein levels.
  • Use of an S10-non-phosphorylatable p27 mutant (A10-p27) to assess dominant-negative effects.

Main Results:

  • atRA treatment increased S10 phospho-p27 levels in CAOV3 cells, accompanied by decreased skp2 levels.
  • Resistant SKOV3 cells did not show these changes.
  • The A10-p27 mutant impaired atRA's effects on p27/CDK interactions, CDK activity, and S-phase gene expression, conferring resistance.

Conclusions:

  • Phosphorylation of p27 at S10 is a critical mechanism for all trans retinoic acid-induced growth arrest in ovarian cancer.
  • Targeting p27 phosphorylation could be a strategy to overcome resistance to atRA in ovarian carcinoma.

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...